Actively Recruiting
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Led by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated on 2025-03-11
128
Participants Needed
1
Research Sites
418 weeks
Total Duration
On this page
Sponsors
L
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
C
CancerCare Manitoba
Collaborating Sponsor
AI-Summary
What this Trial Is About
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.
CONDITIONS
Official Title
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary hepatobiliary cancer confirmed by pathology
- Non-lymphoma liver metastases confirmed by pathology
- Liver lesions consistent with metastases on imaging, in a patient with known non-lymphoma cancer
- Hepatocellular carcinoma diagnosed by imaging and elevated AFP in cirrhosis or chronic hepatitis
- Up to 5 measurable liver lesions on contrast-enhanced CT or MRI within 90 days before study entry
- Liver lesion or metastases measuring 25 cm or less
- Extrahepatic cancer allowed if liver disease is life-limiting
- All liver tumors must be included in radiation fields as per protocol
- Medically or surgically unresectable
- Zubrod Performance Scale 0 to 3
- Age over 18
- All intrahepatic disease must be suitable for TACE
- Previous liver surgery or ablative therapy allowed
- Chemotherapy completed at least 2 weeks before radiation or TACE and not planned for at least 1 week after treatment
- Life expectancy greater than 6 months
- Women of childbearing potential and men must use effective contraception
- Signed informed consent prior to entry
- Required pretreatment evaluations including physical exam and lab tests meeting specific blood count and liver function levels
You will not qualify if you...
- Severe cirrhosis or liver failure defined as Child Pugh greater than B7
- Liver tumor or metastasis larger than 25 cm
- Prior radiotherapy overlapping study cancer region
- Severe, active illness limiting life expectancy to less than 6 months
- Active hepatitis or significant liver failure
- Pregnancy, nursing, or unwillingness/inability to use contraception if applicable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
London Health Sciences Centre, London Regional Cancer Program
London, Ontario, Canada, N6A 5W9
Actively Recruiting
Research Team
M
Michael Lock, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here